authors
- Han, M
- Murugesan, A
- Bahlis, NJ
- Song, K
- White, D
- Chen, C
- Seftel, MD
- Howsen-Jan, K
- Reece, D
- Stewart, K
- Xie, Y
- Hay, AE
- Shepherd, L
- Djurfeldt, M
- Zhu, L
- Meyer, Ralph
- Chen, BE
- Reiman, T
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
Academic Article
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- August 4, 2016
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1114 Paediatrics and Reproductive Medicine (FoR)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- Canada (MeSH)
- Genetic Predisposition to Disease (MeSH)
- Hematopoietic Stem Cell Transplantation (MeSH)
- Humans (MeSH)
- Immunology (Science Metrix)
- Maintenance Chemotherapy (MeSH)
- Melphalan (MeSH)
- Multiple Myeloma (MeSH)
- Pharmacogenomic Testing (MeSH)
- Polymorphism, Single Nucleotide (MeSH)
- Prednisone (MeSH)
- Randomized Controlled Trials as Topic (MeSH)
- Survival Analysis (MeSH)
- Thalidomide (MeSH)
- Transplantation, Autologous (MeSH)
published in
- Blood Journal